✦ LIBER ✦

Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube, and peritoneal cancers

✍ Scribed by Ferriss, J.S.; Java, J.; Burger, R.A.; Bookman, M.A.; Fleming, G.; Monk, B.J.; Walker, J.L.; Homesley, H.D.; Fowler, J.M.; Greer, B.E.; Boente, M.P.

Book ID: 127342905
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 54 KB
Volume: 133
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2014.03.082

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of outpatient first-lin

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

✍ J.P. MICHA; B.H. GOLDSTEIN; M.A. RETTENMAIER; M. GENESEN; C. GRAHAM; K. BADER; K 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Patterns of recurrence in advanced epith

Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy

✍ Katharine M. Esselen; Noah Rodriguez; Whitfield Growdon; Carolyn Krasner; Neil S 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 263 KB

Bevacizumab Combination Therapy: A Revie

Bevacizumab Combination Therapy: A Review of its Use in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

✍ Dhillon, Sohita 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 503 KB

Prospective investigation of risk factor

Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: A Gynecologic Oncology Group study

✍ R. Burger; M. Brady; M. Bookman; B. Monk; J. Walker; H. Homesley; J. Fowler; B. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Independent radiologic review of the Gyn

Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer

✍ Burger, Robert. A.; Brady, Mark F.; Rhee, Joon; Sovak, Mika A.; Kong, George; Ng 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 393 KB

Independent radiologic review of OCEANS,

Independent radiologic review of OCEANS, a phase III trial of carboplatin, gemcitabine, and bevacizumab or placebo for the treatment of platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

✍ C. Aghajanian; S. Makhija; T. Rutherford; S. Sharma; L. Nycum; M. Sovak; H. Nguy 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 136 KB